Moderna, Inc.MRNA

時価総額

$126.7億

PER

mRNA医薬品の大手。mRNAワクチンや治療候補を展開。メルクとの提携や2016年の協業開始、2022年10月のオプション行使で2.5億ドル受領。2024年の製品売上は31億ドル、現金等は95億ドル保有。米国・欧州・アジアで展開。

	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Cash and cash equivalents	658	236	2,624	6,848	3,205	2,907	1,927
Investments	863	867	1,984	3,879	6,697	5,697	5,098
Accounts receivable, net	12	5	1,391	3,175	1,385	892	358
Inventory	-	-	47	1,441	949	202	117
Prepaid expenses and other current assets	28	19	252	728	1,195	627	599
Total current assets	1,563	1,129	6,298	16,071	13,431	10,325	8,099
Investments, non-current	173	160	639	6,843	8,318	4,677	2,494
Property, plant and equipment, net	-	201	297	1,241	2,018	1,945	2,196
Operating Lease, Right-of-Use Asset	-	86	90	142	121	713	759
Other non-current assets	3	2	2	34	988	685	594
Total assets	1,962	1,589	7,337	24,669	25,858	18,426	14,142
Accounts payable	31	7	18	302	487	520	405
Accrued liabilities	79	68	470	1,472	2,101	1,798	1,427
Deferred revenue	-	63	3,867	6,253	2,038	568	153
Other current liabilities	3	5	34	225	249	66	221
Total current liabilities	223	143	4,389	9,128	4,923	3,015	2,206
Deferred revenue, non-current	-	139	177	615	673	83	58
Operating Lease, Liability, Noncurrent	-	94	97	106	92	643	671
Finance Lease, Liability, Noncurrent	-	39	110	599	912	575	39
Other non-current liabilities	0	0	2	76	135	256	267
Total liabilities	432	415	4,775	10,524	6,735	4,572	3,241
Preferred Stock, Value, Issued	-	-	-	-	-	-	-
Common Stock, Value, Issued	0	0	0	-	-	-	-
Additional paid-in capital	2,538	2,669	4,802	4,211	1,173	371	866
Accumulated other comprehensive loss	-1	2	3	-24	-370	-123	-10
Retained earnings	-1,000	-1,496	-2,240	9,958	18,320	13,606	10,045
Total stockholders’ equity	1,530	1,175	2,561	14,145	19,123	13,854	10,901
Total liabilities and stockholders’ equity	1,962	1,589	7,337	24,669	25,858	18,426	14,142